cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.6084/m9.figshare.29207704.v2
title: Aortic valve phenotype and distal aortic outcome after ascending aortic surgery

description: Recent guidelines advocate postoperative aortic surveillance without clear distinction between aortic valve phenotypes. We sought to determine the long-term occurrence and location of distal aortic complications and aortic growth rates postoperatively in patients with bicuspid and tricuspid aortic valves, respectively. Patients underwent elective ascending aorta replacement, with or without concomitant aortic valve surgery, and computed tomography of the aorta preoperatively. Repeat imaging was performed 10 years after surgery and medical records were reviewed to identify aortic events. Overall, 127 patients (bicuspid <i>n</i> = 85 [66.9%], tricuspid <i>n</i> = 42 [33.1%]; male <i>n</i> = 88 [69.3%]) were included at baseline. Ten patients (23.8%) in the tricuspid group developed an acute aortic event, indication for surgery at a distal segment, or underwent aortic intervention, compared with two (2.4%) in the bicuspid group (<i>p</i> &lt; 0.001). 96 patients (75.6%, bicuspid <i>n</i> = 67, tricuspid <i>n</i> = 29) returned for repeat aortic imaging, with a median follow-up of 10.8 years. The frequency of arch complications was significantly higher in the tricuspid group (<i>n</i> = 4 vs. <i>n</i> = 0, <i>p</i> = 0.007). Multivariable logistic regression identified tricuspid aortic valve (OR 8.52, <i>p</i> = 0.012) and baseline distal aortic diameter (OR 1.27 per mm increment, <i>p</i> &lt; 0.001) as risk factors for a distal aortic complication. Patients with a tricuspid aortic valve are at high risk of a distal aortic complication, whereas patients with a bicuspid aortic valve are at low risk. Long-term surveillance should be individualized accordingly.
DOI: 10.6084/m9.figshare.29391815
title: Long-term adherence to flecainide as a rhythm control therapy in recurrent atrial fibrillation – a retrospective cohort study

description: <i>Background</i>. Flecainide is a first-line rhythm control treatment for patients with atrial fibrillation (AF), however long-term treatment outcomes are understudied. <i>Objective</i>. To investigate associations of electro- (ECG) and echocardiographic indices with safety and efficacy outcomes of long-term flecainide treatment for recurrent AF. <i>Methods</i>. Consecutive patients with AF admitted for in-hospital flecainide initiation over a 5-year period were retrospectively included (<i>n</i> = 130, age 60 ± 12 years, 65% males, 29% with persistent AF). Baseline ECGs were processed using the 12SL algorithm. P-wave duration (PWD), Deep terminal negativity of the P-wave in lead V1 (DTNP-V1), left atrial volume index (LAVI), valvular dysfunction and right ventricular fractional area change (RV-FAC) were assessed. The primary endpoint was flecainide discontinuation for any reason. Secondary endpoints were discontinuation due to rhythm control failure and rhythm-related adverse events. <i>Results</i>. After hospital discharge, 120 patients were followed for a median of 1.5 years (interquartile range 0.34–3.1). During follow-up 31% discontinued flecainide, 14% due to rhythm control failure and 10% due to rhythm-related adverse events. Flecainide discontinuation was associated with PWD ≥130 ms (HR 3.65, [1.36–9.75]), DTNP-V1 &gt; 0.1 mV (HR 3.78, [1.15–12.4]), LAVI &gt;48 ml/m<sup>2</sup> (HR 4.43, [2.02–9.70]), moderate mitral regurgitation (HR 4.40, [1.57–12.4]), and RV-FAC &lt;35% (HR 2.30, [1.03–5.16]). Rhythm control failure was associated with PWD, DTNP-V1, LAVI and moderate mitral regurgitation. Rhythm-related adverse events were associated with RV-FAC, LAVI and moderate mitral regurgitation. <i>Conclusion</i>. ECG and echocardiographic indices were associated with discontinuation of flecainide, including safety and efficacy outcomes in long-term treated patients with AF.
DOI: 10.6084/m9.figshare.29391815.v4
title: Long-term adherence to flecainide as a rhythm control therapy in recurrent atrial fibrillation – a retrospective cohort study

description: <i>Background</i>. Flecainide is a first-line rhythm control treatment for patients with atrial fibrillation (AF), however long-term treatment outcomes are understudied. <i>Objective</i>. To investigate associations of electro- (ECG) and echocardiographic indices with safety and efficacy outcomes of long-term flecainide treatment for recurrent AF. <i>Methods</i>. Consecutive patients with AF admitted for in-hospital flecainide initiation over a 5-year period were retrospectively included (<i>n</i> = 130, age 60 ± 12 years, 65% males, 29% with persistent AF). Baseline ECGs were processed using the 12SL algorithm. P-wave duration (PWD), Deep terminal negativity of the P-wave in lead V1 (DTNP-V1), left atrial volume index (LAVI), valvular dysfunction and right ventricular fractional area change (RV-FAC) were assessed. The primary endpoint was flecainide discontinuation for any reason. Secondary endpoints were discontinuation due to rhythm control failure and rhythm-related adverse events. <i>Results</i>. After hospital discharge, 120 patients were followed for a median of 1.5 years (interquartile range 0.34–3.1). During follow-up 31% discontinued flecainide, 14% due to rhythm control failure and 10% due to rhythm-related adverse events. Flecainide discontinuation was associated with PWD ≥130 ms (HR 3.65, [1.36–9.75]), DTNP-V1 &gt; 0.1 mV (HR 3.78, [1.15–12.4]), LAVI &gt;48 ml/m<sup>2</sup> (HR 4.43, [2.02–9.70]), moderate mitral regurgitation (HR 4.40, [1.57–12.4]), and RV-FAC &lt;35% (HR 2.30, [1.03–5.16]). Rhythm control failure was associated with PWD, DTNP-V1, LAVI and moderate mitral regurgitation. Rhythm-related adverse events were associated with RV-FAC, LAVI and moderate mitral regurgitation. <i>Conclusion</i>. ECG and echocardiographic indices were associated with discontinuation of flecainide, including safety and efficacy outcomes in long-term treated patients with AF.
DOI: 10.6084/m9.figshare.28004431
title: CircFNDC3B inhibits vascular smooth muscle cells proliferation in abdominal aortic aneurysms by targeting the miR-1270/PDCD10 axis

description: <i>Objectives</i>. This study investigated the role and underlying regulatory mechanisms of circular RNA fibronectin type III domain containing 3B (circFNDC3B) in abdominal aortic aneurysm (AAA). <i>Methods.</i> The expression of circFNDC3B in AAA and normal tissues was assessed by quantitative real-time reverse transcription polymerase chain reaction (qRT-PCR). To evaluate the biological functions of circFNDC3B, assays were employed including 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2-H-tetrazolium bromide (MTT), flow cytometry, and Caspase-3 activity assays. Additionally, RNA immunoprecipitation (RIP), dual-luciferase reporter assay, Western blotting, and rescue experiments were utilized to elucidate the molecular mechanism of circFNDC3B. <i>Results.</i> Our findings revealed a significant upregulation of circFNDC3B expression in AAA clinical specimens compared to normal tissues. Functionally, overexpression of circFNDC3B inhibited vascular smooth muscle cells (VSMCs) proliferation and induced apoptosis, contributing to AAA formation in the Ang II-induced AAA model. Mechanistically, circFNDC3B acted as a molecular sponge for miR-1270, leading to the upregulation of programmed cell death 10 (PDCD10). Decreased expression of PDCD10 abrogated the -promoting effects of circFNDC3B overexpression on AAA development. <i>Conclusions.</i> This study demonstrates that circFNDC3B promotes the progression of AAA by targeting the miR-1270/PDCD10 pathway. Our findings suggest that circFNDC3B as well as miR-1270/PDCD10 pathway may serve as a potential therapeutic target for AAA treatment.
DOI: 10.6084/m9.figshare.28004431.v1
title: CircFNDC3B inhibits vascular smooth muscle cells proliferation in abdominal aortic aneurysms by targeting the miR-1270/PDCD10 axis

description: <i>Objectives</i>. This study investigated the role and underlying regulatory mechanisms of circular RNA fibronectin type III domain containing 3B (circFNDC3B) in abdominal aortic aneurysm (AAA). <i>Methods.</i> The expression of circFNDC3B in AAA and normal tissues was assessed by quantitative real-time reverse transcription polymerase chain reaction (qRT-PCR). To evaluate the biological functions of circFNDC3B, assays were employed including 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2-H-tetrazolium bromide (MTT), flow cytometry, and Caspase-3 activity assays. Additionally, RNA immunoprecipitation (RIP), dual-luciferase reporter assay, Western blotting, and rescue experiments were utilized to elucidate the molecular mechanism of circFNDC3B. <i>Results.</i> Our findings revealed a significant upregulation of circFNDC3B expression in AAA clinical specimens compared to normal tissues. Functionally, overexpression of circFNDC3B inhibited vascular smooth muscle cells (VSMCs) proliferation and induced apoptosis, contributing to AAA formation in the Ang II-induced AAA model. Mechanistically, circFNDC3B acted as a molecular sponge for miR-1270, leading to the upregulation of programmed cell death 10 (PDCD10). Decreased expression of PDCD10 abrogated the -promoting effects of circFNDC3B overexpression on AAA development. <i>Conclusions.</i> This study demonstrates that circFNDC3B promotes the progression of AAA by targeting the miR-1270/PDCD10 pathway. Our findings suggest that circFNDC3B as well as miR-1270/PDCD10 pathway may serve as a potential therapeutic target for AAA treatment.
DOI: 10.6084/m9.figshare.29391815.v3
title: Long-term adherence to flecainide as a rhythm control therapy in recurrent atrial fibrillation – a retrospective cohort study

description: <i>Background</i>. Flecainide is a first-line rhythm control treatment for patients with atrial fibrillation (AF), however long-term treatment outcomes are understudied. <i>Objective</i>. To investigate associations of electro- (ECG) and echocardiographic indices with safety and efficacy outcomes of long-term flecainide treatment for recurrent AF. <i>Methods</i>. Consecutive patients with AF admitted for in-hospital flecainide initiation over a 5-year period were retrospectively included (<i>n</i> = 130, age 60 ± 12 years, 65% males, 29% with persistent AF). Baseline ECGs were processed using the 12SL algorithm. P-wave duration (PWD), Deep terminal negativity of the P-wave in lead V1 (DTNP-V1), left atrial volume index (LAVI), valvular dysfunction and right ventricular fractional area change (RV-FAC) were assessed. The primary endpoint was flecainide discontinuation for any reason. Secondary endpoints were discontinuation due to rhythm control failure and rhythm-related adverse events. <i>Results</i>. After hospital discharge, 120 patients were followed for a median of 1.5 years (interquartile range 0.34–3.1). During follow-up 31% discontinued flecainide, 14% due to rhythm control failure and 10% due to rhythm-related adverse events. Flecainide discontinuation was associated with PWD ≥130 ms (HR 3.65, [1.36–9.75]), DTNP-V1 &gt; 0.1 mV (HR 3.78, [1.15–12.4]), LAVI &gt;48 ml/m<sup>2</sup> (HR 4.43, [2.02–9.70]), moderate mitral regurgitation (HR 4.40, [1.57–12.4]), and RV-FAC &lt;35% (HR 2.30, [1.03–5.16]). Rhythm control failure was associated with PWD, DTNP-V1, LAVI and moderate mitral regurgitation. Rhythm-related adverse events were associated with RV-FAC, LAVI and moderate mitral regurgitation. <i>Conclusion</i>. ECG and echocardiographic indices were associated with discontinuation of flecainide, including safety and efficacy outcomes in long-term treated patients with AF.
DOI: 10.6084/m9.figshare.29435552
title: Prevalence of atrial fibrillation among Swedish adults participating in the general population study EpiHealth

description: <i>Objectives.</i> This study aimed to estimate the prevalence of atrial fibrillation (AF) and identify its associated comorbidities in adults aged 45 years and older, using data from the Swedish general population study EpiHealth. <i>Design.</i> In a cross-sectional design, data of health history, lifestyle factors, anthropometric measurement, and 1-lead ECG recordings from participants in the EpiHealth study were linked to data from the Swedish Patient Registry. <i>Results.</i> Among the 22,616 participants (56.2% women), the overall prevalence of AF was 3.9%, of which 0.3% were newly diagnosed cases identified by single 1-lead ECG at cohort examination. AF prevalence was higher in men than in women across all age groups and increased with age, reaching 17.2% among men aged 75 years and older. Participants with AF had a higher prevalence of cardiovascular comorbidities compared to those without AF. <i>Conclusions.</i> The findings highlight the increasing prevalence of AF with advancing age and its higher occurrence in men compared to women. The screening-detected prevalence of AF of 0.3% among participants in this general population study suggests that simple 1-lead ECG could be a manageable approach to screen for AF. The strong association between AF and cardiovascular comorbidities emphasizes the need for management strategies to address this condition, particularly in older adults.
DOI: 10.6084/m9.figshare.29435552.v1
title: Prevalence of atrial fibrillation among Swedish adults participating in the general population study EpiHealth

description: <i>Objectives.</i> This study aimed to estimate the prevalence of atrial fibrillation (AF) and identify its associated comorbidities in adults aged 45 years and older, using data from the Swedish general population study EpiHealth. <i>Design.</i> In a cross-sectional design, data of health history, lifestyle factors, anthropometric measurement, and 1-lead ECG recordings from participants in the EpiHealth study were linked to data from the Swedish Patient Registry. <i>Results.</i> Among the 22,616 participants (56.2% women), the overall prevalence of AF was 3.9%, of which 0.3% were newly diagnosed cases identified by single 1-lead ECG at cohort examination. AF prevalence was higher in men than in women across all age groups and increased with age, reaching 17.2% among men aged 75 years and older. Participants with AF had a higher prevalence of cardiovascular comorbidities compared to those without AF. <i>Conclusions.</i> The findings highlight the increasing prevalence of AF with advancing age and its higher occurrence in men compared to women. The screening-detected prevalence of AF of 0.3% among participants in this general population study suggests that simple 1-lead ECG could be a manageable approach to screen for AF. The strong association between AF and cardiovascular comorbidities emphasizes the need for management strategies to address this condition, particularly in older adults.
DOI: 10.17605/osf.io/e6m5a
title: The Effect of Civic Lessons on the Political Engagement of First-Time Voters: A Randomised Control Trial in Bogor City

description: This paper evaluates how in-person civic learning workshops impact voter turnout, engagement and political behaviour of first-time voters, aged 18-21, from Bogor City, in the 2024 Indonesian Presidential Election. The paper also tests if the use of online chat groups aids in sustaining the effects of offline civic lessons.
DOI: 10.5281/zenodo.17223168
title: The UAH Predictions of the Solar Wind and Magnetic Field at the Parker Solar Probe during Solar Encounter 23 (2025-03-25)

description: 1. Model

The MS-FLUKSS heliospheric MHD model is coupled with the WSA model (Kim et al. 2020), which used ADAPT-GONG input magnetograms, with the PFSS source surface height and the WSA outer boundary at 2.5 and 21.5 solar radii, respectively. The MHD model propagates the solar wind from 21.5 solar radii to 236 solar radii (1.1 AU) to fully enclose the PSP trajectory. Hence, field line tracing from PSP to the solar surface is performed through the MHD domain down to 21.5 solar radii instantaneously at approximately 1 hour cadence, where the origin of the field line on the photosphere is already known in the WSA model. See Badman et al. (2023) for details.

MS-FLUKSS: Multi-Scale Fluid-Kinetic Simulation Suite

MHD: Magnetohydrodynamic

WSA: Wang-Sheeley-Arge

ADAPT: Air Force Data Assimilative Photospheric flux Transport

GONG: Global Oscillation Network Group

PFSS: Potential Field Source Surface

PSP: Parker Solar Probe

 

2. Data

There are two sets of data files as described below:

(A) "PSP_AGONG_R000.dat" - "PSP_AGONG_R011.dat": MS-FLUKSS simulation results extracted along the PSP trajectory labeled by the input magnetogram (each of the 12 realizations of ADAPT-GONG) for the WSA model. 

Each data file consist of a header and 16 columns of numerical values in the following order:

(1) Time (fractional year)

(2) Heliocentric distance (AU)

(3) MS-FLUKSS longitude (rotated by ~180 degrees from inertial heliographic longitude in degrees)

(4) MS-FLUKSS latitude (same as heliographic latitude in degrees)

(5) Solar wind proton number density (cm^-3)

(6) Solar wind Vr (km/s)

(7) Solar wind Vphi (km/s)

(8) Solar wind Vtheta (km/s)

(9) Thermal pressure of solar wind and interstellar pickup ion mixture (picodyne/cm^2)

(10) Br (microgauss)

(11) Bphi (microgauss)

(12) Btheta (microgauss)

(13) Level set value for tracking the heliospheric current sheet

(14) Level set value for tracking the initial MS-FLUKSS longitude at the inner boundary

(15) Level set value for tracking the initial MS-FLUKSS latitude at the inner boundary

(16) Solar wind temperature.

 

(B) "UAH_psp_e23_20250325*_agongWSAmhd.csv": Carrington longitude and latitude of the predicted magnetic footpoint from 2025-03-25 to 2025-04-01.

 

Each data file consists of 4 columns of numeric values in the following order:

(1) Date (YYYY-MM-DD)

(2) Time (hh:mm:ss in UT)

(3) Carrington longitude (degree)

(4) Carrington latitude (degree)

 

Note that the tracking values in the original MHD simulation data files contain an interpolation error across 0 (360) degree longitude, so we manually corrected the error in the footpoint coordinates files.

 

3. Figures

There is one figure showing plots of predicted Br, Vr, density, and temperature at PSP: uah_psp_e23_20250325_agongWSAmhd.pdf.

A plot showing the footpoint prediction results projected onto the solar disk is available at the PSP science gateway, at https://psp-gateway.jhuapl.edu/website/SciencePlanning/MissionEvents/, under “Encounter 25”.
DOI: 10.5281/zenodo.17223169
title: The UAH Predictions of the Solar Wind and Magnetic Field at the Parker Solar Probe during Solar Encounter 23 (2025-03-25)

description: 1. Model

The MS-FLUKSS heliospheric MHD model is coupled with the WSA model (Kim et al. 2020), which used ADAPT-GONG input magnetograms, with the PFSS source surface height and the WSA outer boundary at 2.5 and 21.5 solar radii, respectively. The MHD model propagates the solar wind from 21.5 solar radii to 236 solar radii (1.1 AU) to fully enclose the PSP trajectory. Hence, field line tracing from PSP to the solar surface is performed through the MHD domain down to 21.5 solar radii instantaneously at approximately 1 hour cadence, where the origin of the field line on the photosphere is already known in the WSA model. See Badman et al. (2023) for details.

MS-FLUKSS: Multi-Scale Fluid-Kinetic Simulation Suite

MHD: Magnetohydrodynamic

WSA: Wang-Sheeley-Arge

ADAPT: Air Force Data Assimilative Photospheric flux Transport

GONG: Global Oscillation Network Group

PFSS: Potential Field Source Surface

PSP: Parker Solar Probe

 

2. Data

There are two sets of data files as described below:

(A) "PSP_AGONG_R000.dat" - "PSP_AGONG_R011.dat": MS-FLUKSS simulation results extracted along the PSP trajectory labeled by the input magnetogram (each of the 12 realizations of ADAPT-GONG) for the WSA model. 

Each data file consist of a header and 16 columns of numerical values in the following order:

(1) Time (fractional year)

(2) Heliocentric distance (AU)

(3) MS-FLUKSS longitude (rotated by ~180 degrees from inertial heliographic longitude in degrees)

(4) MS-FLUKSS latitude (same as heliographic latitude in degrees)

(5) Solar wind proton number density (cm^-3)

(6) Solar wind Vr (km/s)

(7) Solar wind Vphi (km/s)

(8) Solar wind Vtheta (km/s)

(9) Thermal pressure of solar wind and interstellar pickup ion mixture (picodyne/cm^2)

(10) Br (microgauss)

(11) Bphi (microgauss)

(12) Btheta (microgauss)

(13) Level set value for tracking the heliospheric current sheet

(14) Level set value for tracking the initial MS-FLUKSS longitude at the inner boundary

(15) Level set value for tracking the initial MS-FLUKSS latitude at the inner boundary

(16) Solar wind temperature.

 

(B) "UAH_psp_e23_20250325*_agongWSAmhd.csv": Carrington longitude and latitude of the predicted magnetic footpoint from 2025-03-25 to 2025-04-01.

 

Each data file consists of 4 columns of numeric values in the following order:

(1) Date (YYYY-MM-DD)

(2) Time (hh:mm:ss in UT)

(3) Carrington longitude (degree)

(4) Carrington latitude (degree)

 

Note that the tracking values in the original MHD simulation data files contain an interpolation error across 0 (360) degree longitude, so we manually corrected the error in the footpoint coordinates files.

 

3. Figures

There is one figure showing plots of predicted Br, Vr, density, and temperature at PSP: uah_psp_e23_20250325_agongWSAmhd.pdf.

A plot showing the footpoint prediction results projected onto the solar disk is available at the PSP science gateway, at https://psp-gateway.jhuapl.edu/website/SciencePlanning/MissionEvents/, under “Encounter 25”.
DOI: 10.60893/figshare.apl.30260359
title: Supplemental materials

description: Details of derivation of equations
DOI: 10.60893/figshare.apl.30260359.v1
title: Supplemental materials

description: Details of derivation of equations